Table 1.
Biochemical responses and timing of liver biopsy in mipomersen-treated patients*
| Case | Rx (weeks) |
Max ALT, (week) |
Biopsy week |
Baseline LDL-c (mg/dL) |
Final LDL-c (mg/dL |
Baseline apoB (mg/dL) |
Final apoB (mg/dL) |
Initial IHTG % (week) |
IHTG on treatment % (week) |
|---|---|---|---|---|---|---|---|---|---|
| 1† | 25 | 126 (36) | 22 | 209 | 85 | 146 | 77 | 17.8 (4) | 34.7 (18) |
| 2† | 26 | 160 (28) | 21 | 167 | 56 | 126 | 40 | 23.7 (11) | 47.3 (30) 27.0 (50) |
| 3 | 35 | 103 (28) | 34 | 94 | 23 | 90 | 28 (28) 31 (36) |
2.5 (1) | 33.9 (28) 36.1 (36) |
| 4 | 52 | 126 (52) | 47 | 121 | 52 | 113 | 46 | 2 (1) | 23.6 (44) |
| 5 | 100 | 94 (43) | 73 | 264 | 124 | 171 | 92 | 36.7 (52) | 35.8 (100) |
| 6 | 159 | 79 (129†) | 159‡ | 562 | 376 | 349 | 221 | <1 (39) | <1 (156) |
| 7 | 60 | 200 (26) | 56 | 195 | na§ | 126 | na§ | 5.6 | na§ |
*
Abbreviations: LDL-c, low-density lipoprotein cholesterol; apoB, apolipoprotein B; IHTG, intrahepatic triglyceride
†
Biopsy previously reported, but reanalyzed as part of this study.4
‡
This patient was treated with mipomersen for 104 weeks, followed by a 28 week hiatus, and then treated for 55 more weeks.
§
na – Values are not available because the patients remains enrolled in a blinded study.